[Juvenile spongy dystrophy of CNS with necrosis of the medulla. A. complication of hydroxyquinoline therapy (author's transl)].
A girl of 10-5/12 years is described, who had diabetes mellitus from the age of 5 years on and who developed bilateral ptosis, pigment degeneration of the retina and bilateral impairment of hearing at the age of nine years. A few weeks before death she suffered from an acute gastrointestinal infection which was successfully treated by a hydroxyquinoline derivative. In the days following a severe encephalopathy and signs of cardiac involvement appeared. A month later the girl died of bulbar paralysis and acute heart failure. Histology showed remnants of a granulomatous inflammation in the heart, the kidneys, the pancreas and the skeletal muscles. Furthermore there was a widespread spongiosis in the white substance of the brain, with large astrocytes, and partly also in the basal ganglia, the brain stem and the cerebellum. Foci of sudanophilic tissue necrosis resembling Wernicke's Encephalopathy were found in the medulla oblongata and the spinal cord. The peripheral nerves appeared partially demyelinated and showed axonal lesions. This case is classified as a Juvenile Type of so-called Canavan's Disease. It shows some resemblence to the "Progressive Chronic Ophthalmoplegia with Spongiform Encephalopathy described by Daroff, Kearn and Sayre. The possible neurotoxical effects of the hydroxyquinoline therapy are discussed.
D001921:Brain / Q000473:pathology; D001927:Brain Diseases / Q000139:chemically induced* / Q000209:etiology / Q000473:pathology; D002648:Child; D048909:Diabetes Complications; D005260:Female; D005767:Gastrointestinal Diseases / Q000188:drug therapy; D006801:Humans; D006912:Hydroxyquinolines / Q000009:adverse effects*; D007049:Iatrogenic Disease; D008526:Medulla Oblongata / Q000473:pathology*; D009132:Muscles / Q000473:pathology; D009206:Myocardium / Q000473:pathology; D010179:Pancreas / Q000473:pathology
D006912:Hydroxyquinolines
Juvenile spongiöse Dystrophie des ZNS mit Medullanekrose. Komplikation einer Hydroxychinolin-Behandlung?